{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:14:32Z","timestamp":1787026472736,"version":"build-2736575974"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02493","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:41:38Z","timestamp":1571704898000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":33,"title":["NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors"],"prefix":"10.3389","volume":"10","author":[{"given":"Jani-Sofia","family":"Almeida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia","family":"Couceiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"L\u00f3pez-Sejas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"R\u016f\u017ei\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Tarazona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Solana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Freitas-Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Santos-Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Rodrigues-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0950-3536(87)80035-5","article-title":"The BCR\/ABL hybrid gene","volume":"1","author":"Groffen","year":"1987","journal-title":"Baillieres Clin Haematol"},{"key":"B5","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"142","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.2174\/092986711798184271","article-title":"Effects of BCR-ABL inhibitors on anti-tumor immunity","volume":"18","author":"Krusch","year":"2011","journal-title":"Curr Med Chem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/blood-2012-11-465039","article-title":"Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling","volume":"122","author":"de Lavallade","year":"2013","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"81852","DOI":"10.18632\/oncotarget.20965","article-title":"Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment","volume":"8","author":"Yao","year":"2017","journal-title":"Oncotarget"},{"key":"B13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bbmt.2017.10.039","article-title":"Immunomodulatory effects of tyrosine kinase inhibitor in vitro and in vivo study","volume":"24","author":"Marinelli Busilacchi","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune effector recovery in chronic myeloid leukemia and treatment-free remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors","volume":"25","author":"Bantscheff","year":"2007","journal-title":"Nat Biotechnol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4161\/cbt.27310","article-title":"Large granular lymphocytosis during dasatinib therapy","volume":"15","author":"Qiu","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nri1309","article-title":"NKT cells: what's in a name?","volume":"4","author":"Godfrey","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.exger.2007.05.002","article-title":"Invariant NKT and NKT-like lymphocytes: two different T cell subsets that are differentially affected by ageing","volume":"42","author":"Peralbo","year":"2007","journal-title":"Exp Gerontol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/eji.201142043","article-title":"Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients","volume":"42","author":"Rossignol","year":"2012","journal-title":"Eur J Immunol."},{"key":"B24","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.4049\/jimmunol.136.12.4480","article-title":"The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes","volume":"136","author":"Lanier","year":"1986","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1084\/jem.164.1.351","article-title":"A subset of natural killer cells in peripheral blood displays a mature T cell phenotype","volume":"164","author":"Schmidt","year":"1986","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/0008-8749(91)90369-M","article-title":"Comparative studies of CD3- and CD3+ CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression","volume":"136","author":"Ortaldo","year":"1991","journal-title":"Cell Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.4049\/jimmunol.1300111","article-title":"Multiplex and genome-wide analyses reveal distinctive properties of KIR+ and CD56+ T cells in human blood","volume":"191","author":"Chan","year":"2013","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3390\/ijms19020440","article-title":"The janus face of NKT cell function in autoimmunity and infectious diseases","volume":"19","author":"Torina","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/art.22310","article-title":"CD56-expressing T cells that have features of senescence are expanded in rheumatoid arthritis","volume":"56","author":"Michel","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B30","doi-asserted-by":"publisher","first-page":"9675861","DOI":"10.1155\/2016\/9675861","article-title":"Effect of Interleukin-15 on CD11b, CD54, and CD62L Expression on natural killer cell and natural killer T-like cells in systemic lupus erythematosus","author":"Lin","year":"2016","journal-title":"Mediators Inflamm"},{"key":"B31","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.healun.2012.04.007","article-title":"Bronchiolitis obliterans syndrome is associated with increased peripheral blood natural killer and natural killer T-like granzymes, perforin, and T-helper-type 1 pro-inflammatory cytokines","volume":"31","author":"Hodge","year":"2012","journal-title":"J Hear Lung Transplant"},{"key":"B32","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1053\/jhep.2000.19362","article-title":"Decrease of CD56+ T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma","volume":"32","author":"Kawarabayashi","year":"2000","journal-title":"Hepatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"9292","DOI":"10.1128\/JVI.00834-07","article-title":"Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection","volume":"81","author":"Golden-Mason","year":"2007","journal-title":"J Virol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/j.1365-2893.2008.01036.x","article-title":"Alterations in natural killer cells and natural killer T cells during acute viral hepatitis","volume":"15","author":"Srivastava","year":"2008","journal-title":"E. J Viral Hepat"},{"key":"B35","first-page":"21","article-title":"NKT-like cells are expanded in solid tumour patients","volume":"25","author":"Zdrazilova-Dubska","year":"2012","journal-title":"Klin Onkol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4149\/BLL_2018_002","article-title":"Decline in peripheral blood NKG2D+CD3+CD56+ NKT cells in metastatic colorectal cancer patients","volume":"119","author":"Gharagozloo","year":"2018","journal-title":"Bratisl Med J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3892\/or_00000924","article-title":"Natural Killer-like T CD3+\/CD16+CD56+ cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome","volume":"24","author":"Bojarska-junak","year":"2010","journal-title":"Oncol Rep"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1007\/s12032-012-0262-4","article-title":"Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia","volume":"29","author":"Jadidi-Niaragh","year":"2012","journal-title":"Med Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","article-title":"Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy","volume":"85","author":"Rohon","year":"2010","journal-title":"Eur J Haematol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"W566","DOI":"10.1093\/nar\/gkv468","article-title":"ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap","volume":"43","author":"Metsalu","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B41","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood."},{"key":"B42","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst."},{"key":"B43","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood."},{"key":"B44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"key":"B45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1200\/JCO.2016.67.0893","article-title":"Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia","volume":"35","author":"Sopper","year":"2017","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00432-015-2101-4","article-title":"Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia","volume":"142","author":"El Missiry","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/ni.1693","article-title":"Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function","volume":"10","author":"Cruz-Munoz","year":"2009","journal-title":"Nat Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/1521-4141(200101)31:1<233::AID-IMMU233>3.3.CO;2-W","article-title":"Identification of NKp80, a novel triggering molecule expressed by human NK cells","volume":"31","author":"Vitale","year":"2001","journal-title":"Eur J Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","article-title":"Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML","volume":"32","author":"Br\u00fcck","year":"2018","journal-title":"Leukemia"},{"key":"B51","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/bjh.13467","article-title":"Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model","volume":"170","author":"Gassner","year":"2015","journal-title":"Br J Haematol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1182\/blood-2018-04-845834","article-title":"Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma","volume":"132","author":"Kamijo","year":"2018","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"134","DOI":"10.4103\/ejh.ejh_39_17","article-title":"Programmed death receptor ligand-1 plasma concentration in chronic myeloid leukemia under first- line tyrosine kinase inhibitor therapy","volume":"42","author":"Elkhawanky","year":"2017","journal-title":"Egypt J Haematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02493\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T18:54:14Z","timestamp":1695322454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02493\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2019.02493"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02493","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"article-number":"2493"}}